WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2007005608) IL-12/P40 BINDING PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/005608    International Application No.:    PCT/US2006/025584
Publication Date: 11.01.2007 International Filing Date: 29.06.2006
Chapter 2 Demand Filed:    29.01.2007    
C07K 16/00 (2006.01)
Applicants: ABBOTT LABORATORIES [US/US]; 100 Abbott Park Road Abbott Park, IL 60064 (US) (For All Designated States Except US).
LACY, Susan E. [CA/US]; (US) (For US Only).
FUNG, Emma [CA/US]; (US) (For US Only).
BELK, Jonathan P. [US/US]; (US) (For US Only).
DIXON, Richard W. [US/US]; (US) (For US Only).
ROGUSKA, Michael [US/US]; (US) (For US Only).
HINTON, Paul R. [US/US]; (US) (For US Only).
KUMAR, Shankar [US/US]; (US) (For US Only)
Inventors: LACY, Susan E.; (US).
FUNG, Emma; (US).
BELK, Jonathan P.; (US).
DIXON, Richard W.; (US).
ROGUSKA, Michael; (US).
HINTON, Paul R.; (US).
KUMAR, Shankar; (US)
Agent: SESHADRI, Tara; Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605-4314, (US)
Priority Data:
60/695,679 30.06.2005 US
Abstract: front page image
(EN)The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
(FR)La présente invention concerne des protéines de liaison à l'IL-12p40, en particulier des anticorps qui se lient à l'interleukine-12 humaine (hIL-12) et/ou à l'interleukine-23 humaine (hIL-23). Cette invention concerne spécifiquement des anticorps qui sont des anticorps chimères, à greffage de CDR et humanisés. Des anticorps préférés présentent une forte affinité pour l'interleukine-12 humaine et/ou l'interleukine-23 humaine et neutralisent l'activité de l'interleukine-12 humaine et/ou de l'interleukine-23 humaine in vitro et in vivo. Un anticorps de cette invention peut être un anticorps complet ou une partie de liaison à l'antigène de celui-ci. Cette invention concerne également un procédé de production et un procédé d'utilisation des anticorps de cette invention. Les anticorps ou les parties d'anticorps de cette invention servent à détecter l'interleukine-12 humaine et/ou l'interleukine-23 humaine et à inhiber l'activité de l'interleukine-12 humaine et/ou de l'interleukine-23 humaine, par exemple chez un sujet humain souffrant d'un trouble dans lequel l'activité de l'interleukine-12 humaine et/ou de l'interleukine-23 humaine est nuisible.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)